Joyce O’Shaughnessy, MD, discusses the design, goals, and significance of the IMpassion130 study that looked at the use of atezolizumab in combination with nab-paclitaxel for patients with previously untreated metastatic triple-negative breast cancer (TNBC).

For more resources and information regarding anticancer targeted therapies: [ Ссылка ]

свернуть